Efficacy and Safety of Risankizumab in the Treatment of Crohn's Disease of the Pouch
Risankizumab has shown efficacy in the treatment of moderate-to-severe Crohn's disease (CD). The use of risankizumab in the treatment of CD of the pouch has not been previously reported. Here, we have 10 patients with biologics exposed CD of the pouch treated with risankizumab. Some patients showed endoscopic improvement regarding inflammation with minimal clinical improvement. Our findings warrant further study to validate the efficacy and safety of risankizumab in the treatment of CD of the pouch.
Authors
- Bo Shen (ORCID: https://orcid.org/0000-0002-7229-4840)
- Nan Lan
Institutions
- NewYork–Presbyterian Hospital (US)
- New York Hospital Queens (US)
- Columbia University (US)
Publication Details
- Journal
- ACG Case Reports Journal
- Published
- 2024-08-29
- DOI
- https://doi.org/10.14309/crj.0000000000001476
- Citations
- 2
- Primary Topic
- Inflammatory Bowel Disease
- Type
- article
- Field-Weighted Citation Impact
- 1.10